Actinogen Medical
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAActinogen Medical Limited (ACW, formerly Actinogen Limited) is an ASX-listed biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. It focusses on the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases within Australia.
Contact Details
Suite 901, Level 9, 109 Pitt St, SYDNEY NSW 2000
02 8964 7401
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 361st | Actinogen Medical | 43% | -5% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Actinogen Medical | $9.9m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEWS: Tagged in Coking coal elbows antimony sideways to take centre stage | 30 Aug 2024 |
| NEWS: Tagged in New money sends InteliCare share price flying | 28 Jun 2024 |
| NEW ROLE: Dana Hilt, | 04 Sep 2023 |
| NEW ROLE: Paul Rolan, | 03 Jan 2023 |
| NEW ROLE: Steven Gourlay, Chief Executive Officer, Managing Director | 13 Apr 2022 |
| NEW ROLE: Jeff Carter, | 01 Mar 2022 |
| NEW ROLE: Tamara Miller, | 01 Mar 2022 |
| REMUNERATION UPDATE: Malcolm McComas, Non-Executive Director | 03 Nov 2020 |
| REMUNERATION UPDATE: Bill Ketelbey, Chief Executive Officer, Managing Director | 03 Nov 2020 |
